Drug Trial Radar · NCT06186804
A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)
Last checked: Nov 19, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
64
Planned (sponsor's estimate)
Start
May 30, 2023
Primary completion
Oct 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, single arm, open label phase II clinical study in China. This study will evaluate the efficacy and safety of ABSK021 (Pimicotinib) in the treatment of patients with cGvHD who failed first-line therapy.
Conditions
- cGvHD
Interventions
ABSK021Drug
Patients in each phase and dose group will receive continuous treatment with oral administration once a day for 28 days/cycle until conditions for treatment termination are met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limited toxicity (DLT) at each dose can assess the incidence of DLT in patients during the observation period of DLT (Part A only)Time frame: Starting from the first medication, observe for 31 days
- Overall response rate after 6 cycles of treatmentTime frame: 6 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
The Second Affiliated Hospital of the Army Medical University
Chongqing, Chongqing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Guangdong Provincial Peoplep's Hospital
Guangzhou, Guangdong, China
ZhuJiang Hospital of Southern Medical University
Zhujiang, Guangdong, China
Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology
Wuhan, Hubei, China
Union Hospital, Tongji Medical College,Huazhong University of Science and Technology
Wuhan, Hubei, China
The Fir St Affiliated Hospital,Zhejiang Univer Sity School of Medicine
Hangzhou, Jiangsu, China
The First affiliated hospital of SuZhou University
Suzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The First Hospital of Jilin University
Changchun, Jilin, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Hematology Hospital of Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
The First Teaching Hospital of Xinjiang Medical University
Xinjiang, Xinjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.